HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS

单纯疱疹病毒异源结合疫苗

基本信息

批准号：
2645270
负责人：
Daniel Hill Zimmerman
金额：
$ 10万
依托单位：
CEL-SCI CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-06-01 至 1999-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2645270
关键词：
Herpesviridae vaccine T lymphocyte disease /disorder prevention /control herpes simplex virus 1 immunity laboratory mouse ligands peptides synthetic vaccines vaccine development virus antigen virus protein

项目摘要

DESCRIPTION: (Adapted from the applicant's abstract) The primary goal of this program is the development of heteroconjugate peptide vaccines against herpes simplex virus to prevent or treat human infections. The heteroconjugate peptide vaccines will be constructed of epitopes from herpes simplex virus proteins which are recognized by T cells and peptides which are predicted to bind to T cells (T cell binding ligands (TCBL)). The TCBL appears to potentiate the immunogenicity of the antigenic peptide and to guide the course of the immune response to be either more cellular (TH1) or humoral (TH2). These heteroconjugates will be tested for their ability to elicit protective immune responses to HSV-1 and HSV-2 in mouse models for HSV disease. The TCBL are peptide sequences from different lymphocyte surface binding proteins. The successful vaccine will elicit TH1 type (including delayed type hypersensitivity) protective immune responses to viral challenge in mouse models. The HSV vaccines will be prototypes for the development of heteroconjugate vaccines to treat or prevent disease by other infectious agents. PROPOSED COMMERCIAL APPLICATION: The urgent need for a vaccine for HSV is shown by the over 60,000,000 persons in the U.S. being infected and subject to recurrent HSV infections from laten virus. The first objective, a therapeutic vaccine could be of tremendous benefit in reducing and/or eliminating the severity and number of recurrent infections. The second objective, a preventive vaccine of HSV to eliminate the underlying cause could ultimately have a major impact in eliminating latent infections, if the vaccine induced a sterilizing immunity. The second objective also does not require the first objective of a therapeutic vaccine be reached. Cel-Sci is developing a similar approach for a HIV vaccine and is in phase II trials in Europe for a preventive vaccine to evaluate its immunogenicity. the Company expects to start a phase II trial in Africa within 6 months. Cel-Sci has plans to start a phase I trial for a HIV therapeutic vaccine candidate in the U.S. using this L.E.A.P.S. technology within a year.

描述：（根据申请人的摘要进行了改编）主要目标该程序的开发是杂轭肽疫苗的开发针对单纯疱疹病毒预防或治疗人类感染。这杂结轭肽疫苗将由来自 T细胞识别的单纯疱疹病毒蛋白质和预测与T细胞结合的肽（T细胞结合配体（TCBL））。 TCBL似乎可以增强抗原肽并指导免疫反应的过程更细胞（TH1）或体液（TH2）。这些异量轭将测试他们引起保护性免疫反应的能力用于HSV疾病的小鼠模型中的HSV-1和HSV-2。 TCBL是来自不同淋巴细胞表面结合蛋白的肽序列。成功的疫苗将引起Th1类型（包括延迟类型超敏反应）对病毒挑战的保护性免疫反应鼠标模型。 HSV疫苗将是开发的原型杂结轭疫苗以治疗或预防其他疾病感染者。拟议的商业应用：超过60,000,000显示了对HSV疫苗的迫切需求美国的人被感染并受到复发性HSV的影响来自拉登病毒的感染。第一个目标，一种治疗性疫苗在减少和/或消除巨大的好处重复感染的严重性和数量。第二个目标，一个 HSV的预防性疫苗以消除根本原因最终在消除潜在感染的情况下会产生重大影响疫苗诱导了一种消毒免疫。第二个目标也确实不需要达到治疗疫苗的第一个目标。 Cel-SCI正在为HIV疫苗开发类似的方法，并且正在欧洲的第二阶段试验预防性疫苗评估其免疫原性。该公司预计将在非洲开始II期审判在6个月内。 Cel-SCI计划开始对艾滋病毒的I期审判美国使用此L.E.A.P.S.的治疗疫苗候选者一年之内的技术。